Friday, 16 October 2026European Markets

PRODWAYS Stock Over 22% Down In The Last 10 Sessions

Loading stream...

(vianews) - shares of prodways (cac 40: pwg.pa) fell by a staggering 22.17% in 10 sessions from €2.03 to €1.58 at 11:07 est on tuesday, following the last session's downward trend. cac 40 is rising 0.12% to €7,193.31, following the last session's upward trend.

prodways's last close was €1.63, 59.2% below its 52-week high of €3.99.

about prodways

prodways group sa manufactures and sells industrial and professional 3d printers in france and internationally. the company operates in two segments, systems and products. it offers machines, such as 3d printing systems that include lost wax, dlp15resin, and laser sintering; and other related premium materials and services, as well as offers 3d design, simulation, and optimization software. the company also provides metal and plastic parts; orthopedic insoles for podiatry application; orthodontic pieces and dental trays, mouthpieces dental application; and hearing aid tips and custom hearing protection products for audiology application. it serves aerospace and defence, healthcare, automotive, consumer goods, and jewellery sectors. prodways group sa was founded in 2013 and is headquartered in paris, france.

earnings per share

as for profitability, prodways has a trailing twelve months eps of €0.03.

pe ratio

prodways has a trailing twelve months price to earnings ratio of 52.8. meaning, the purchaser of the share is investing €52.8 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.4%.

volume

today's last reported volume for prodways is 3885 which is 16.24% below its average volume of 59594.

more news about prodways (pwg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com